VOR

+ Watchlist + Portfolio

Vor Biopharma Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $23.58
52-Week Range: $6.50 – $50.20
Market Cap: $1.36B
P/E (TTM): 0.13
EPS (TTM): 176.64
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -21.37%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 19.15
Debt/Equity: —
Total Debt: $2.88M
Free Cash Flow: $-79.50M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $901.33M

VOR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$64.55M	$94.31M	$93.31M	$321.53M
Selling, General & Admin	$28.87M	$31.72M	$27.88M	$50.11M
Operating Expenses	$93.42M	$126.04M	$121.19M	$371.64M
Operating Income	-$93.42M	-$126.04M	-$121.19M	-$371.64M
EBITDA	-$90.89M	-$122.54M	-$117.66M	-$368.75M
Pretax Income	-$92.09M	-$117.86M	-$116.91M	-$695.98M
Net Income	-$92.09M	-$117.86M	-$116.91M	-$695.98M
Diluted EPS	-46.60	-35.00	-34.03	-70.50
Diluted Shares	1.98M	3.36M	3.44M	9.87M

VOR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$57.71M	$31.36M	$81.95M	$396.49M
Current Assets	$236.95M	$140.80M	$96.51M	$458.11M
Total Assets	$299.37M	$198.13M	$142.89M	$464.13M
Current Liabilities	$13.12M	$15.57M	$18.61M	$25.17M
Total Debt	$38.91M	$35.66M	$31.83M	$3.00M
Total Liabilities	$48.76M	$47.40M	$46.23M	$628.44M
Retained Earnings	-$222.22M	-$340.08M	-$456.99M	-$1.15B
Shareholders' Equity	$250.61M	$150.72M	$96.66M	-$164.31M
Working Capital	$223.83M	$125.23M	$77.89M	$432.93M

VOR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$85.14M	-$100.29M	-$99.66M	-$142.71M
Capital Expenditure	-$8.46M	-$1.07M	-$229.00K	-$941.00K
Free Cash Flow	-$93.61M	-$101.36M	-$99.89M	-$143.65M
Depreciation & Amortisation	$2.52M	$3.49M	$3.53M	$2.89M
Stock-Based Compensation	$10.70M	$13.36M	$9.85M	$18.91M
Investing Cash Flow	-$94.09M	$71.01M	$96.86M	-$48.80M
Financing Cash Flow	$117.14M	$2.94M	$53.39M	$503.81M
Net Change in Cash	-$62.09M	-$26.35M	$50.59M	$312.29M

VOR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$26.70M	$261.50M	$14.14M	$19.19M	$17.59M
Selling, General & Admin	$6.59M	$12.79M	$13.96M	$16.77M	$17.57M
Operating Expenses	$33.29M	$274.28M	$28.11M	$35.96M	$35.16M
Operating Income	-$33.29M	-$274.28M	-$28.11M	-$35.96M	-$35.16M
EBITDA	-$32.47M	-$272.25M	-$28.11M	-$35.94M	-$35.13M
Pretax Income	-$32.49M	-$1.57B	-$812.68M	$1.72B	-$219.59M
Net Income	-$32.49M	-$1.57B	-$812.68M	$1.72B	-$219.59M
Diluted EPS	-5.21	-251.20	-121.63	—	-5.11
Diluted Shares	6.24M	6.26M	6.68M	—	43.01M

VOR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$50.05M	$190.57M	$160.46M	$396.49M	$169.87M
Current Assets	$64.85M	$204.93M	$172.49M	$458.11M	$500.78M
Total Assets	$109.31M	$205.37M	$176.24M	$464.13M	$506.75M
Current Liabilities	$16.73M	$58.77M	$18.84M	$25.17M	$16.08M
Total Debt	$30.78M	$0.00	$3.06M	$3.00M	$2.94M
Total Liabilities	$43.24M	$1.71B	$2.40B	$628.44M	$657.17M
Retained Earnings	-$489.48M	-$2.06B	-$2.88B	-$1.15B	-$1.37B
Shareholders' Equity	$66.07M	-$1.51B	-$2.23B	-$164.31M	-$150.42M
Working Capital	$48.12M	$146.15M	$153.65M	$432.93M	$484.70M

VOR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$31.07M	-$35.18M	-$53.66M	-$22.80M	-$38.25M
Capital Expenditure	-$231.00K	-$152.00K	-$244.00K	-$314.00K	-$48.00K
Free Cash Flow	-$31.30M	-$35.34M	-$53.91M	-$23.11M	-$38.29M
Depreciation & Amortisation	$825.00K	$2.04M	$2.00K	$23.00K	$28.00K
Stock-Based Compensation	$1.93M	$1.84M	$8.03M	$7.11M	$8.87M
Investing Cash Flow	-$230.00K	$646.00K	-$244.00K	-$48.97M	-$263.24M
Financing Cash Flow	-$606.00K	$175.06M	$21.55M	$307.80M	$74.87M
Net Change in Cash	-$31.90M	$140.53M	-$32.36M	$236.02M	-$226.61M

Market Snapshot

About

Vor Biopharma Inc. is a clinical-stage cell and genome engineering company focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company uses its proprietary platform to enable targeted therapies in combination with stem cell transplants. Vor is working to improve outcomes for patients with blood cancers and solid tumors.